Patterns of Practice of Regional Nodal Irradiation in Breast Cancer: Results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal RAdiotherapy (NORA) Survey
Menée à partir d'une enquête en ligne auprès de 84 centres de lutte contre le cancer du réseau de l'organisation européenne pour la recherche et le traitement du cancer, cette étude analyse les différentes pratiques en matière de radiothérapie ciblant les ganglions régionaux chez les patientes atteintes d'un cancer du sein
Background : Predicting outcome of breast cancer (BC) patients based on sentinel lymph node (SLN) status without axillary lymph node dissection (ALND) is an area of uncertainty. It influences the decision making for regional nodal irradiation (RNI). The aim of the NORA (NOdal RAdiotherapy) Survey was to examine the patterns of RNI.
Methods : A web-questionnaire, including several clinical scenarios was distributed to 88 EORTC-affiliated centers. Responses were received between July 2013 and January 2014.
Results : A total of 84 responses were analyzed. While 3D-radiotherapy (RT) planning is performed in 81(96%) centers, nodal areas are delineated in only 51(61%) centers. Only 14(17%) centers routinely link internal mammary chain (IMC) and supraclavicular node (SCN) RT indications. In patients undergoing total mastectomy (TM) with ALND, SCN-RT is recommend by 5(6%), 53(63%) and 51(61%) centers for patients with pN0(i+), pN(mi) and pN1, respectively. Extra-capsular extension (ECE) is the main factor influencing decision-making RNI after breast conserving surgery (BCS) and TM. After primary systemic therapy (PST), 49 (58%) centers take into account nodal fibrotic changes in ypN0 patients for RNI indications. In ypN0 patients with inner/central tumors, 23(27%) centers indicate SCN-RT and IMC-RT. In ypN1 patients, SCN-RT is delivered by less than half of the centers in patients with ypN(i+) and ypN(mi). Twenty-one (25%) of the centers recommend ALN-RT in patients with ypN(mi) or 1-2N+ after ALND. Seventy-five (90%) centers state that age is not considered a limiting factor for RNI.
Conclusion : The NORA Survey is unique in evaluating the impact of SLNB/ALND status on adjuvant RNI decision-making and volumes after BCS/TM with or without PST. ALN-RT is often indicated in pN1 patients, particularly in case of ECE. Beside the ongoing NSABP-B51/RTOG and ALLIANCE trials, NORA could help to design future specific RNI trials in the SLNB era without ALND in patients receiving or not PST.
Annals of Oncology , résumé, 2014